The costs and quality-of-life outcomes of drug-eluting coronary stents: A systematic review

Journal of Interventional Cardiology

Volumn 20, Issue 1, 2007, Pages 1-9

  Groeneveld, Peter W ^a,b,c,d   Suh, Janice J ^b   Matta, Mary Anne ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d 1229 Blockley Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING STENT; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESTENOSIS; REVASCULARIZATION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; DRUG DELIVERY SYSTEMS; HEALTH CARE COSTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; STENTS; UNITED STATES;

EID: 33846547142     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2007.00214.x     Document Type: Review

References (34)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
3. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-1545.
4. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-1099.
5. Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: A randomized trial. JAMA 2004;292:2727-2734.
6. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
7. Wokhlu A, Jollis JG. Dollars and stents: The economics of drug-eluting stents. Am Heart Hosp J 2005;3:94-98, 104.
8. Lemos PA, Serruys PW, Sousa JE. Drug-eluting stents: Cost versus clinical benefit. Circulation 2003;107:3003-3007.
9. Ward MR. Cost-benefit of drug eluting stents - time for a reality check. Heart Lung Circ 2005;14:74-77.
10. Kong DF, Eisenstein EL. Decision models for assessing the cost effectiveness of drug-eluting stents. Expert Opin Pharmacother 2005;6:965-974.
11. Heart and Stroke Foundation. Targeting new health technology - who needs drug eluting stents? Available at: http://ww2.heartandstroke.ca/Page.asp?PageID= 33&ArticleID=4294&Src=news&From=SubCategory. Accessed March 27, 2006.
12. Dillon A. Technology Appraisal Guidance 71: Guidance on the Use of Coronary Artery Stents. London: National Institute for Clinical Excellence, October 2003.
13. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 2004;110:508-514.
14. Rinfret S, Cohen DJ, Tahami Monfared AA, et al. Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: An analysis from the C-SIRIUS Trial. Am J Cardiovasc Drugs 2006;6:159-168.
15. Kling J. The lucrative elution: Boston Scientific's blockbuster medical device - and the novel way it was developed. Technol Rev October 2005:75-82. Available at: www.technologyreview.com/BizTech/14819. Accessed April 11, 2006.
16. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol 2004;43:513-518.
17. Gold MR. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
18. Hartling L, McAlister FA, Rowe BH, et al. Challenges in systematic reviews of therapeutic devices and procedures. Ann Intern Med 2005;142:1100-1111.
19. Gilbert SP, Weintraub WS, Talley JD, et al. Costs of coronary restenosis (Lovastatin Restenosis Trial). Am J Cardiol 1996;77:196-199.
20. Greenberg D, Bakhai A, Neumann PJ, et al. Willingness to pay for avoiding coronary restenosis and repeat revascularization: Results from a contingent valuation study. Health Policy 2004;70:207-216.
21. Rinfret S, Grines CL, Cosgrove RS, et al. Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the Stent-PAMI trial. J Am Coll Cardiol 2001;38:1614-1621.
22. Weaver WD, Reisman MA, Griffin JJ, et al. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): A randomised trial. Lancet 2000;355:2199-2203.
23. Shrive FM, Manns BJ, Galbraith PD, et al. Economic evaluation of sirolimus-eluting stents. CMAJ 2005;172:345-351.
24. Borkon AM, Muehlebach GF, House J, et al. A comparison of the recovery of health status after percutaneous coronary intervention and coronary artery bypass. Ann Thorac Surg 2002;74:1526-1530; discussion 1530.
25. Ladwig KH, Muhlberger N, Walter H, et al. Gender differences in emotional disability and negative health perception in cardiac patients 6 months after stent implantation. J Psychosom Res 2000;48:501-508.
26. Cohen DJ, Taira DA, Berezin R, et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: Results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation 2001;104:3039-3045.
27. Gold MR, ed. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
28. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-1641.
29. Bagust A, Grayson AD, Palmer ND, et al. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: Costutility study. Heart 2006;92:68-74.
30. Bakhai A, Stone GW, Mahoney E, et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: Results from the TAXUS-IV Trial. J Am Coll Cardiol 2006;48:253-261.
31. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005;366:921-929.
32. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006;354:483-495.
33. Tung R, Kaul S, Diamond GA, et al. Narrative review: Drug-eluting stents for the management of restenosis: A critical appraisal of the evidence. Ann Intern Med 2006;144:913-919.
34. van Hout BA, Serruys PW, Lemos PA, et al. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: An analysis from the RAVEL trial. Heart 2005;91:507-512.